{"filing":{"accession_number":"0001840199-26-000066","cik":"0001840199","ticker":"WALDW","company_name":"Waldencast plc","form":"6-K","filing_date":"2026-06-15","report_date":null,"primary_document":"wald6-k_luminaamendment2.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840199/000184019926000066/wald6-k_luminaamendment2.htm"},"events":[{"id":12298,"run_id":10864,"accession_number":"0001840199-26-000066","anchor_item_number":"EX-99.2","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces FDA approval of Obagi® saypha® ChIQ™, a new injectable hyaluronic acid gel product for the Obagi Medical brand (owned by Waldencast). The approval expands Obagi's injectable portfolio and strengthens its position in the dermal filler market. This is a material operational/product milestone—a regulatory approval that materially expands the company's addressable market in the fast-growing U.S. dermal filler category and advances its strategy to establish Obagi as a comprehensive leader in medical aesthetics. While not a discrete M\u0026A, litigation, or financial event, the approval of a new product with significant market potential is material to investors assessing the company's growth trajectory and competitive positioning.","company_name":"Waldencast plc","ticker":"WALDW","filing_date":"2026-06-15","form":"6-K","submitted_at":null,"items":[{"id":9112,"accession_number":"0001840199-26-000066","item_number":"EX-99.2","item_title":"chiq_launchxpressxreleasex.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces FDA approval of Obagi® saypha® ChIQ™, a new injectable hyaluronic acid gel product for the Obagi Medical brand (owned by Waldencast). The approval expands Obagi's injectable portfolio and strengthens its position in the dermal filler market. This is a material operational/product milestone—a regulatory approval that materially expands the company's addressable market in the fast-growing U.S. dermal filler category and advances its strategy to establish Obagi as a comprehensive leader in medical aesthetics. While not a discrete M\u0026A, litigation, or financial event, the approval of a new product with significant market potential is material to investors assessing the company's growth trajectory and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:35:12.424834+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9112,"accession_number":"0001840199-26-000066","item_number":"EX-99.2","item_title":"chiq_launchxpressxreleasex.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces FDA approval of Obagi® saypha® ChIQ™, a new injectable hyaluronic acid gel product for the Obagi Medical brand (owned by Waldencast). The approval expands Obagi's injectable portfolio and strengthens its position in the dermal filler market. This is a material operational/product milestone—a regulatory approval that materially expands the company's addressable market in the fast-growing U.S. dermal filler category and advances its strategy to establish Obagi as a comprehensive leader in medical aesthetics. While not a discrete M\u0026A, litigation, or financial event, the approval of a new product with significant market potential is material to investors assessing the company's growth trajectory and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:35:12.424834+00:00","company_name":"Waldencast plc","ticker":"WALDW","filing_date":"2026-06-15"}]}